Table Of ContentInfl ammatory Breast Cancer: An Update
Naoto T. Ueno • Massimo Cristofanilli
Editors
Infl ammatory Breast Cancer:
An Update
Editors
Naoto T. Ueno, M.D., Ph.D., F.A.C.P. Massimo Cristofanilli
Morgan Welch Infl ammatory Breast Department of Medical Oncology
Cancer Program and Clinic Fox Chase Cancer Center
Department of Breast Medical Oncology Cottman Avenue, Room C315 333
The University of Texas Philadelphia, PA, USA
MD Anderson Cancer Center
Unit 1354, Holcombe Blvd. 1515
Houston, TX, USA
ISBN 978-94-007-3906-2 ISBN 978-94-007-3907-9 (eBook)
DOI 10.1007/978-94-007-3907-9
Springer Dordrecht Heidelberg New York London
Library of Congress Control Number: 2012935582
© Springer Science+Business Media B.V. 2012
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of
the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation,
broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information
storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology
now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection
with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and
executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this
publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s
location, in its current version, and permission for use must always be obtained from Springer. Permissions
for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to
prosecution under the respective Copyright Law.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication
does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant
protective laws and regulations and therefore free for general use.
While the advice and information in this book are believed to be true and accurate at the date of
publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for
any errors or omissions that may be made. The publisher makes no warranty, express or implied, with
respect to the material contained herein.
Printed on acid-free paper
Springer is part of Springer Science+Business Media (www.springer.com)
Contents
1 Introduction: Why IBC Now? ............................................................... 1
Naoto T. Ueno and Massimo Cristofanilli
2 Epidemiology of Infl ammatory Breast Cancer .................................... 3
Shannon Wiggins, Sarah Taylor, and Melissa Bondy
3 Clinical Aspect of Infl ammatory Breast Cancer:
Diagnosis, Criteria, Controversy ........................................................... 11
Shaheenah Dawood and Vicente Valero
4 Infl ammatory Breast Cancer Registry .................................................. 21
Jie S. Willey and Naoto T. Ueno
5 Pathology: Histomorphometrical Features
of IBC – Angiogenesis, Lymphangiogenesis, and Tumor Emboli ....... 27
Sanford H. Barsky and Fredika M. Robertson
6 Imaging for the Diagnosis and Staging of IBC ..................................... 53
Wei Tse Yang
7 Surgical Therapy for Infl ammatory Breast Cancer ............................ 67
Sarah M. Gainer, Hideko Yamauchi, and Anthony Lucci
8 Radiation Therapy for Infl ammatory Breast Cancer .......................... 75
Thomas A. Buchholz, Ian Bristol, and Wendy Woodward
9 Systemic and Targeted Therapy ............................................................ 85
Hideko Yamauchi, Teruo Yamauchi,
Naoto T. Ueno, and Vicente Valero
10 Infl ammatory Breast Cancer: Chemotherapy
of Metastatic Disease ............................................................................... 101
Anthony Gonçalves and Patrice Viens
v
vi Contents
11 The Role of the Multidisciplinary Team
in Infl ammatory Breast Cancer ............................................................. 121
Nabila Chowdhury and Sandra M. Swain
12 High-Dose Chemotherapy with Autologous Hematopoietic
Stem Cell Transplantation in Infl ammatory Breast Cancer ............... 127
Yee Chung Cheng and Naoto T. Ueno
13 Models of Infl ammatory Breast Cancer................................................ 139
Lara Lacerda and Wendy A. Woodward
14 Signaling Pathways in Infl ammatory Breast Cancer ........................... 151
Dongwei Zhang and Naoto T. Ueno
15 Molecules That Drive the Invasion and Metastasis
of Infl ammatory Breast Cancer ............................................................. 161
Madhura Joglekar and Kenneth L. van Golen
16 Infl ammatory Mediators as Therapeutic Targets
for Infl ammatory Breast Cancer ........................................................... 185
Fredika M. Robertson, Khoi Chu, Rita Circo, Julia Wulfkuhle,
Lance Liotta, Annie Z. Luo, Kimberly M. Boley, Erik M. Freiter,
Hui Liu, Pijus K. Mandal, John S. McMurray, Massimo Cristofanilli,
and Emanuel F. Petricoin
17 Immunology of Infl ammatory Breast Cancer ...................................... 207
James M. Reuben and Bang-Ning Lee
18 Angiogenesis and Lymphangiogenesis in IBC: Insights
from a Genome-Wide Gene Expression Profi ling Study ..................... 225
Peter B. Vermeulen, Gert Van den Eynden, Pascal Finetti,
Daniel Birnbaum, Naoto T. Ueno, Patrice Viens,
François Bertucci, Luc Y. Dirix, and Steven J. Van Laere
19 Microarray Analysis Identifi es an Expression
Signature for Infl ammatory Breast Cancer .......................................... 243
François Bertucci, Pascal Finetti, Max Chaffanet,
Patrice Viens, and Daniel Birnbaum
20 Cell Gene Expression Signatures
in Infl ammatory Breast Cancer ............................................................. 259
Wendy A. Woodward
21 The Effect of Systemic Chemotherapy on Minimal
Residual Disease in the Blood and Bone Marrow
of Patients with Infl ammatory Breast Cancer ...................................... 271
Luc Y. Dirix, Dieter Peeters, Steven Van Laere, and Peter B. Vermeulen
22 Perspective of Patient Advocacy ............................................................ 281
Michelle Esteban and Patti Bradfi eld
Index ................................................................................................................. 291
Chapter 1
Introduction: Why IBC Now?
Naoto T. Ueno and Massimo Cristofanilli
We are truly honored to provide the fi rst textbook related to infl ammatory breast
cancer. This infl ammatory breast cancer is rare but the most aggressive form of
breast cancer. Despite it has a distinct clinical presentation, we have yet to establish
the pathogenesis of this disease. The disease does not have molecularly defi ned
diagnostic criteria and we are not able to establish the defi nitive infl ammatory breast
cancer specifi c treatment. Therefore, there is a strong need for a clinical and a sci-
entifi c advancement of this disease.
The aggressiveness of this disease stems from its rapid locoregional recurrence
and distant metastasis. Therefore, this disease is an excellent disease model to
understand the biology of metastasis, epithelial-mesenchymal transition, stem cell,
microenvironment, etc. Further, the diffuse redness resembling infl ammation allows
speculating immunological and infl ammatory processes are involved in the patho-
genesis of this disease. If we could understand this biology of the disease, it not only
helps infl ammatory breast cancer but other noninfl ammatory breast cancer disease.
Each chapter of this textbook will offer a detailed, comprehensive most up to
date description of infl ammatory breast cancer. We will provide not only the exist-
ing information about this disease but also how this can be incorporated into your
routine clinical practice. This textbook covers imaging, pathology, basic research,
clinical trials, clinical practice, genetic predisposition, and epidemiology. Further,
we have had a special chapter from the patient advocacy perspective of this deadly
N. T. Ueno , M.D., Ph.D., F.A.C.P. (*)
Morgan Welch Infl ammatory Breast Cancer Program and Clinic, Department of Breast
Medical Oncology, The University of Texas, MD Anderson Cancer Center,
Unit 1354, Holcombe Blvd. 1515, Houston, TX, USA
e-mail: [email protected]
M. Cristofanilli
Department of Medical Oncology, Fox Chase Cancer Center ,
Cottman Avenue, Room C315 333 , Philadelphia , PA, USA
e-mail: [email protected]
N.T. Ueno and M. Cristofanilli (eds.), Infl ammatory Breast Cancer: An Update, 1
DOI 10.1007/978-94-007-3907-9_1, © Springer Science+Business Media B.V. 2012
2 N.T. Ueno and M. Cristofanilli
disease. It is always an enthusiastic welcome for cancer survivor, which includes
cancer patients, family and their friend, to participate in the fi ght of this disease.
It is important for the healthcare providers to learn the perspective of cancer survivors.
We hope that this textbook will provide the opportunities to our readers to see who
are in the forefront of this disease research. We highly encourage your participation
and contacting these authors to form collaboration so that we can eliminate the
suffering from this disease.
At the end, we believe that this will be a valuable resource for those who are taking
care of breast cancer. This work is supported in part by The State of Texas Grant for
Rare and Aggressive Cancers through the Morgan Welch Infl ammatory Breast
Cancer Research Program. We would also like to thank Jenna Boatright and,
Danielle Walsh for organizing this book as well as MD Anderson Cancer Center
Scientifi c Publications for its editing assistance.
Chapter 2
Epidemiology of Infl ammatory Breast Cancer
Shannon Wiggins , Sarah Taylor , and Melissa Bondy
Abstract Infl ammatory breast cancer (IBC) is the most aggressive and fatal form
of invasive breast cancer. The disease affects approximately 2.5% of breast cancer
patients in the United States typically with younger age of onset and higher inci-
dence in African-Americans. Incidence rates vary due to the clinical nature, rather
than pathological, of the diagnosis. Changes to the SEER coding rules will also
likely have an impact on IBC reporting rates. Epidemiological observations have
also suggested geographic differences in the incidence of IBC but without resulting
in the identifi cation of risk factors. Few risk factors have been established but asso-
ciations have been noted with African American race and younger age of onset, as
well as high BMI. Decreased survival rates in patients with ER-negative tumors
have also been noted. An ongoing registry is being conducted at The University of
Texas MD Anderson Cancer Center to address this issue. It is a prospective registry,
and although relatively small, some observations of note can be made. The patients
enrolled on the registry have a mean age at diagnosis of 55 years and over half of the
patients present with ER-negative tumors. Also 18% of the patients reported a fi rst-
degree relative with breast cancer. The majority was overweight or obese and were
former or still currently smokers. The registry includes sites in both the United
States and internationally and information collected in the registry will be used in
order to further elucidate the etiology and risk factors for IBC.
S. Wiggins , M.P.H. • M. Bondy , Ph.D.
Dan L. Duncan Cancer Center , Baylor College of Medicine ,
Houston , T X , USA
e-mail: [email protected]; [email protected]
S. Taylor , M.P.H. (*)
Department of Tumor Registry , The University of Texas MD Anderson Cancer Center ,
Houston , T X , USA
e-mail: [email protected]
N.T. Ueno and M. Cristofanilli (eds.), Infl ammatory Breast Cancer: An Update, 3
DOI 10.1007/978-94-007-3907-9_2, © Springer Science+Business Media B.V. 2012
